Named on 6 rounds in the feed, most often at Series A and in Biotech.
Rounds from 2020-11-17 to 2026-07-21
ROUNDS
6
led 2, joined 4
LED ROUNDS · USD
$138.2M
across 2 rounds · 2 co-led, split evenly
CO-INVESTORS
26
named beside it
Named on 6 rounds in the feed, most often at Series A and in Biotech.
Rounds from 2020-11-17 to 2026-07-21
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Meshy Meshy's AI 3D model generator turns text and images into production-ready 3D models in 20-30 seconds. | Series B Verified against 1 of 4 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $400M | 2026-07-21 | [ LEAD ] |
BCI-Sonics A non-invasive AI brain-computer interface company | Pre-seed Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $14.7M | 2026-06-08 | [ LEAD ] |
Galbot Galbot sells advanced AI robotics technology, including humanoid robots and their associated AI models, primarily targeting various industries and homes. | Strategic funding round Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $69.1M | 2024-11-19 | [ PART ] |
D3 Bio D3 Bio develops innovative and efficacious medicines focused on oncology and immunology, targeting unmet patient needs. | Series A Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $62M | 2024-04-08 | [ PART ] |
Klook Klook sells travel experiences and activities, such as tours and attraction tickets, primarily targeting travelers. | Series E Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2021-01-25 | [ PART ] |
D3 Bio D3 Bio develops innovative and efficacious medicines focused on oncology and immunology, targeting unmet patient needs. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2020-11-17 | [ PART ] |